Apabetalone treatment improves cognition in CVD patients with diabetes
Subsequent conference call & webcast scheduled to present BETonMACE prespecified cognition assessment results
CALGARY, Alberta, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX: RVX) today announces that data on apabetalone – and its therapeutic potential for cardiovascular patients experiencing cognitive decline – and the BETonMACE prespecified cognition assessment results will be presented at the Clinical Trials on Alzheimer's Disease (“CtAD”) Congress 2019, held this year in San Diego, USA. On December 5th, 2019, an educational symposium titled: “Epigenetics and the BET-system in vascular dementia, Alzheimer’s disease and mixed dementia – the problem and potential remedies” (the “Symposium”) will take place during CtAD where key opinion leaders will review the role of epigenetics and BET-inhibition as a novel strategy in combatting vascular dementia and Alzheimer’s disease. The details of the Symposium are available below.
"The effects seen in the BETonMACE trial for those with cognitive impairment are very promising and suggest that epigenetic modulators such as apabetalone may represent an important and novel approach to treatment of cognitive disorders,” stated Dr. Jeff Cummings, Vice Chair of Lou Ruvo Brain Health Center, Las Vegas, and one of the presenters during the CtAD Symposium.
Symposium Agenda – December 5th, 2019, 5:00 pm MT
Introduction by chairman Dr. Bengt Winblad, Karolinska Institutet, Sweden.
- Dementias, who and how to treat and by what specialty. Addressing problem and current and potential future therapeutic practices: Dr. Charles DeCarli, UC Davis, USA
- Fluid biomarkers that predict and project brain health: Dr. Henrik Zetterberg, University of Gothenburg, Sweden
- The epigenetic inhibitor Apabetalone corrects pathophysiological brain endothelial and microglial cell activation that contributes to neurodegenerative disease: Dr. Ewelina Kulikowski, Resverlogix Corporation, Canada
- Epigenetics, the BET-system, Alzheimer’s Disease and Vascular Cognitive Impairment; The BETonMACE study and effects of apabetalone 100 mg b.i.d. two years treatment on cognition in diabetes patients with established cardiovascular disease: Dr. Jeffrey Cummings, Cleveland Clinic Lou Ruvo Center for Brain Health, USA
In addition to the Symposium, a poster on the Company’s lead compound – apabetalone, titled: “Epigenetic Modulator Apabetalone Inhibits Monocyte Adhesion To Brain Endothelial Cells By Downregulating Key Neuroinflammation Markers In Vitro And In Vivo”, will be presented by Dr. Ewelina Kulikowski, Senior Vice President, Research & Development, for Resverlogix.
The full conference program, including details on the Company’s poster presentation and the sponsored symposium can be found HERE.
Conference Call & Webcast Details
Additionally, the Company has scheduled a conference call and webcast for 8:30 am ET on December 6, 2019, to supplement the presentation of the BETonMACE cognition results to be made during the Symposium.
For those wishing to join the December 6th event, it is highly recommended to access the webcast over the Internet using the following LINK. A replay of the webcast (using the same link provided) will be available for one month following the conclusion of the event.
If dialing in by phone, dial 1-800-319-4610 (within Canada / USA) or +1-604-638-5340 (International Toll). Callers should dial-in at least 10 min prior to the scheduled start time. A teleconference replay will be available for one month following the conclusion of the event and can be accessed by dialing 1-800-319-6413 (within Canada / USA) or +1-604-638-9010 (International Toll) and using the replay access code: 3912.
Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile.
Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).
Follow us on:
- Twitter: @Resverlogix_RVX
- LinkedIn: https://www.linkedin.com/company/resverlogix-corp-/
For further information please contact:
This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information related to the BETonMACE prespecified cognition assessment results conference call and webcast and the potential role of apabetalone in the treatment of patients with cognitive disorders, high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, Fabry disease, peripheral artery disease and other orphan diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.